FDA Won’t Release Information on Pfizer COVID Vaccine Trials for Another 55 Years – What Are They Hiding?
The FDA is holding back information.
In response to a Freedom of Information Act request (FOIA) filed months ago the FDA has asked a federal judge to give them 55 years to release data related to the Pfizer COVID vaccines.
Americans are currently being forced by the regime to take this vaccine to hold a job but have no rights to see how this “vaccine” was approved.
But their grand-children may get to see the data in 55 years.
The US medical community is losing all trust and credibility.
Via Israel National News.
In response to a Freedom of Information Act request (FOIA) filed over three months ago, in August of 2021, the U.S. Food and Drug Administration (FDA) has asked a federal judge for 55 years to review its data before releasing it to the public in its entirety.
The data refers to the FDA’s decision to license what is now known as the Comirnaty vaccine against Covid-19, produced by Pfizer in collaboration with BioNTech. Back in November of 2020, when considering Pfizer-BioNTech’s request for emergency use authorization (EUA) of its product, the FDA promised that:
“In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Committee … will meet to discuss the totality and safety and effectiveness data provided … The FDA understands there is tremendous public interest regarding vaccines for COVID-19. We remain committed to keeping the public informed about the evaluation of the data … so that once available, the public and the medical community can have trust and confidence in receiving the vaccine for our families and ourselves.”
In September of 2021, when amending its EUA to include booster doses, the FDA reiterated its commitment to transparency, writing:
“As we learn more about the safety and effectiveness of COVID-19 vaccines … we will continue to evaluate the rapidly changing science and keep the public informed…”
The FDA noted at the time that it was studying data provided not only by Pfizer-BioNTech, but also from the “Israeli Ministry of Health, the University of Bristol, U.K. and the Centers for Disease Control and Prevention [CDC].”